NeuroPhage Pharmaceuticals secured $6.4 million in a funding round led by Mérieux Développement. The company will use the proceeds to advance development of its potential Alzheimer's drug NPT002, which is in preclinical development. The firm plans to submit an investigational new drug application and begin clinical trials next year.

Full Story:

Related Summaries